Table 3.
Treatment outcomes of dose escalation cohort (n = 22).
| Cohort | Subject # | Disease type | MET IHC | HGF IHC | DLT | Best response | Duration of treatment (days) |
|---|---|---|---|---|---|---|---|
| 1 (0.3 mg/kg) |
RA101 | CRC | 2+ | 0 | None | PD | 48.0 |
| RA102 | Lung Cancer | 3+ | 0 | None | SD | 98.0 | |
| RA103 | CRC | 3+ | + | None | PD | 0.0 | |
| RA113 | Melanoma | 3+ | n/a | None | SD | 140.0 | |
| 2 (1 mg/kg) |
RA201 | CRC | 0 | 0 | None | SD | 84.0 |
| RA202 | Sarcoma | 3+ | + | None | SD | 99.0 | |
| RA203 | CRC | 2+ | N/A | None | PD | 26.0 | |
| 3 (3 mg/kg) |
RA301 | CRC | 1+ | 2+ | None | SD | 98.0 |
| RA302 | CRC | N/A | 0 | None | PD | 0.0 | |
| RA303 | Basal cell carcinoma | 2+ | N/A | None | SD | 101.0 | |
| 4 (5 mg/kg) |
RA401 | Gastric cancer | 1+ | 2+ | None | PD | 43.0 |
| RA402 | CRC | 2+ | 2+ | None | SD | 156.0 | |
| RA403 | CRC | N/A | N/A | None | PD | 43.0 | |
|
5 (10 mg/kg) |
RA501 | Hepatocellular carcinoma | N/A | N/A | None | SD | 124.0 |
| RA502 | Ovarian ca | 0 | N/A | None | PD | 29.0 | |
| RA503 | Melanoma | 2+ | 1+ | None | SD | 156.0 | |
| 6 (20 mg/kg) |
RA601 | GC | 0 | N/A | None | SD | 126.0 |
| RA602 | Sebaceous carcinoma | 0 | 1+ | None | PR | 503.0 | |
| RA603 | Cervical cancer | 0 | 0 | None | PD | 26.0 | |
| 7 (30 mg/kg) |
RA701 | Sarcoma | 0 | 0 | None | PD | 42.0 |
| RA702 | Ovarian cancer | n/a | 0 | None | PD | 0.0 | |
| RA703 | Ovarian cancer | 2+ | 3+ | None | SD | 41.0 |
CRC, colorectal cancer; DLT, dose-limiting toxicity; HGF, hepatocyte growth factor; IHC, immunohistochemistry; PD, progressive disease; PR, partial response; SD, stable disease.